Clinical trial · Interventional
Pre-Clinic Visit Online Education for Thyroid Cancer
A Randomized Controlled Trial Evaluating Educational Resources for Patients With Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online educational resources among adult patients with thyroid cancer. Each online program can be accessed on the patient's personal device, and will be provided to the patient following a diagnosis of thyroid cancer but before meeting with their surgeon to discuss treatment options. The goal of the resource is to educate patients on the various treatment options for thyroid cancer prior to surgical consultation, so that clinic visit time can be better utilized to discuss patient questions and priorities, and support shared decision making. Clinical (TC-MAX; thyroid cancer related anxiety) and behavioral outcomes (decisional conflict, shared-decision making, treatment decision) will be assessed via online surveys 1-day and 14-days post-visit.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ACS "After a Thyroid Cancer Diagnosis" Flyer | Other | — | UNRESOLVED |
| THRIVE | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- THRIVE
- description
- Participants randomized to the THRIVE arm will be sent a link to access the THRIVE portal up to 3 weeks prior to their clinic visit. The THRIVE modules can take between 20-35 minutes to complete. Completion of the THRIVE modules prior to the clinic visit will be monitored and confirmed by study staff. Upon completing the program, a report summarizing the conversation and questions/comments brought up by the patient will be shared with their physician prior to the clinic visit.
- interventionNames
- Behavioral: THRIVE
- type
- SHAM_COMPARATOR
- label
- Education Control
- description
- Participants randomized to the education control arm will be sent a link to access the 2-page American Cancer Society (ACS) handout: "After a Thyroid Cancer Diagnosis." The handout can take between 5-15 minutes to read through. Completion of the ACS handout prior to the clinic visit will be monitored and confirmed by study staff.
- interventionNames
- Other: ACS "After a Thyroid Cancer Diagnosis" Flyer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed with either: 1. ≤2cm Bethesda 6 thyroid nodule (papillary thyroid carcinoma) (T1N0) 2. ≤2cm Bethesda 5 thyroid nodule 3. ≤2cm Bethesda 3-4 thyroid nodule with molecular testing that confers \>75% risk of malignancy * Able to understand and complete questionnaires independently in English * Access to an internet-enabled device for online surveys and intervention access Exclusion Criteria: * Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation * Has nodule \>2cm in size, or with non-papillary thyroid carcinoma histology * High-grade or poorly differentiated papillary thyroid carcinoma (PTC) variants * Central or lateral neck lymphadenopathy suspicious for PTC * Unfavorable nodule location, to be determined by the surgeon (e.g. Near dorsal surface (by recurrent laryngeal nerve); adjacent to trachea (risk of cartilage invasion) * Recurrent thyroid cancer case
References
Publications (0)
Data not yet available